Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApollomicsAPLM +1.84%31 Debt-to-Equity is -0.20 as of Dec. 2025. GuruFocus rates APLM with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 966 Biotechnology companies, Apollomics ranks worse than 103519.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Apollomics's Debt-to-Equity or its related term are showing as below:
APLM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2 Med: 0 Max: 0.2
Current: -0.2
During the past 6 years, the highest Debt-to-Equity Ratio of Apollomics was 0.20. The lowest was -0.20. And the median was 0.00.
APLM's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs APLM: -0.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Apollomics Debt-to-Equity Related Terms
Apollomics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Apollomics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APLM vs HYPD, MGX, KALA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Apollomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apollomics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apollomics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Apollomics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apollomics (APLM) has a Debt-to-Equity of -0.20 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Apollomics and its competitors. According to the industry distribution chart, Apollomics ranks #999999 out of 966 companies in the Biotechnology industry.
Is Apollomics' Debt-to-Equity too high?
Apollomics' current Debt-to-Equity is -0.20. Based on the distribution chart, Apollomics ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Debt-to-Equity compare to HYPD and MGX?
According to the Biotechnology industry distribution chart, Apollomics ranks #999999 out of 966 companies for Debt-to-Equity. This places Apollomics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Apollomics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apollomics's current Debt-to-Equity is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLM) has a current Debt-to-Equity of -0.20. The current Debt-to-Equity is -0.20. Apollomics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Apollomics (APLM), the current Debt-to-Equity is -0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score
Get the complete analysis for APLM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLM has been successfully added to your 
